甘肃医药2026，Vol.45Issue(3)：223-228,6.DOI:10.15975/j.cnki.1004-2725.2026.03.007
乳酸化驱动胃癌进展与耐药的研究现状
Research progress on lactylation-driven gastric cancer progression and therapeutic resistance
摘要
Abstract
Lactylation is a novel metabolism-dependent post-translational modification that plays a crucial role in the initiation,pro-gression,and therapeutic resistance of gastric cancer.Lactylation not only promotes tumor cell proliferation and metastasis by regulating DNA damage repair,cell cycle progression,apoptotic pathways,and the metabolic tumor microenvironment,but also reduces treatment efficacy by en-hancing immuno suppression and accelerating drug clearance.Currently,major strategies for targeting lactylation in gastric cancer include in-hibiting lactate production,blocking lactate transport,and modulating lactylation-related enzymes and their downstream effectors.The aim of this study is to integrate the existing gastric cancer treatment methods that mainly focus on interfering with the lactate process.The main signifi-cance lies in attempting to promote the transformation of relevant biomarkers into clinical applications,with the expectation of enhancing the precision treatment level for patients with gastric cancer.关键词
乳酸化/胃癌进展/耐药/靶向药物Key words
lactylation/gastric cancer progression/therapeutic resistance/targeted drug分类
医药卫生引用本文复制引用
肖毅,李明煊,马文源,王彦..乳酸化驱动胃癌进展与耐药的研究现状[J].甘肃医药,2026,45(3):223-228,6.基金项目
兰州市科技计划项目(编号:2024-9-30) （编号:2024-9-30）
